Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project.
CONCLUSION:  In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict "sick" patients or poor prognosis overall. PMID: 32506417 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 6, 2020 Category: Hematology Authors: Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V Tags: Thromb Haemost Source Type: research

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Abstract Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against ea...
Source: Thrombosis and Haemostasis - February 28, 2014 Category: Hematology Authors: Skjøth F, Larsen TB, Rasmussen LH, Lip GY Tags: Thromb Haemost Source Type: research

Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation.
Abstract In patients with acute stroke and atrial fibrillation (AF), the risk of early recurrence has been reported to range between 0.1 % and 1.3 % per day. Anticoagulants are the most effective therapy for the prevention of recurrent ischaemic stroke in these patients, but randomised clinical trials have failed to produce any evidence supporting the administration of heparin within 48 hours from stroke onset as it has been associated with a non-significant reduction in the recurrence of ischaemic stroke, no substantial reduction in death and disability, and an increase in intracranial bleeding. As early haem...
Source: Thrombosis and Haemostasis - June 22, 2016 Category: Hematology Authors: Paciaroni M, Agnelli G, Ageno W, Caso V Tags: Thromb Haemost Source Type: research

Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution.
Abstract Stroke prevention is a key clinical concern in the management of patients with atrial fibrillation. Oral anticoagulation treatment reduces the risk of disabling stroke, but the treatment increases the risk of bleeding. For decades, the decision to initiate oral anticoagulation has been guided by clinical risk scoring systems such as the CHADS2 and CHA2DS2-VASc scores. In this narrative review, we focus on the recent discussion of the "Sc" (Sex Category) criterion in the CHA2DS2-VASc score. Epidemiological considerations when assessing stroke rates in cohorts are discussed, and the implications of differen...
Source: Thrombosis and Haemostasis - April 20, 2020 Category: Hematology Authors: Nielsen PB, Overvad TF Tags: Thromb Haemost Source Type: research

Paradoxical Increase of Stroke in Patients with Defect of High Molecular Weight Multimers of the von Willebrand Factors following Transcatheter Aortic Valve Replacement.
CONCLUSION:  MLBCs and CT-ADP > 180 seconds were identified as predictors for ischemic stroke or TIA. The present study suggests that the defects of HMW multimers of the VWFs may contribute not only to bleeding events but also to thrombotic events. PMID: 32726854 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 28, 2020 Category: Hematology Authors: Matsushita K, Marchandot B, Trimaille A, Kibler M, Heger J, Peillex M, Hess S, Grunebaum L, Reydel A, Kindo M, Hoang MT, Sato C, De Poli F, Leddet P, Ohana M, Jesel L, Ohlmann P, Susen S, Morel O Tags: Thromb Haemost Source Type: research

Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: A nationwide population-based study.
CONCLUSIONS: Age is an important determinant of ischemic stroke and composite outcome in intermediate-risk AF patients. The benefit of OAC therapy for these AF patients appears to have an age threshold (age ≥ 55 years). PMID: 33307565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2020 Category: Hematology Authors: Choi SY, Kim MHH, Lee KM, Cho YR, Park JS, Yun SC, Lip GY Tags: Thromb Haemost Source Type: research

Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention
CONCLUSIONS: Monitoring of DOAC plasma levels could help to identify patients with increased risk for stroke recurrence and should be considered for certain subgroups, including patients with high GFR.PMID:35171533 | DOI:10.1111/jth.15677
Source: Thrombosis and Haemostasis - February 16, 2022 Category: Hematology Authors: Gabriela Siedler Kosmas Macha Svenja Stoll Johannes Plechschmidt Ruihao Wang Stefan T Gerner Erwin Strasser Stefan Schwab Bernd Kallm ünzer Source Type: research

Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation.
In conclusion, there was a substantial amount of inter-patient variability, and often extreme differences in opinion regarding tolerance of bleeding risk in the context of stroke prevention in atrial fibrillation. These findings highlight the importance of considering patient preferences when deciding on SPAF therapy. PMID: 24337399 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 12, 2013 Category: Hematology Authors: Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D, Francis K Tags: Thromb Haemost Source Type: research

Stroke prevention in atrial fibrillation: An Asian perspective.
Abstract Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. In 2050, it is estimated that there will be 72 million AF patients in Asia, accounting for almost 2.9 million patients suffering from AF-associated stroke. Asian AF patients share similar risk factor profiles as non-Asians, except that more Asians have a history of previous stroke. Clinical challenges are evident in the field of stroke prevention in AF, amongst Asians. Existing stroke and bleeding risk scores have not been well-validated in Asians. Asians are prone to bleeding when treated with warfarin, and the optimal internationa...
Source: Thrombosis and Haemostasis - February 6, 2014 Category: Hematology Authors: Chiang CE, Wang KL, Lip GY Tags: Thromb Haemost Source Type: research

Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making.
Abstract Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed markedly over the last decade. There has been an evolution over the approach to stroke and bleeding risk assessment, as well as new treatment options. An increasing awareness of AF has led to calls to improve the detection of and population screening for AF. Stroke and bleeding risk assessment continues to evolve, and the ongoing debate on balance between simplicity and practicality, against precision medicine will continue. In this review article, we provide an overview of past, present and the (likely) future conce...
Source: Thrombosis and Haemostasis - June 9, 2017 Category: Hematology Authors: Lip G, Lip GYH, Freedman B, De Caterina R, Potpara TS Tags: Thromb Haemost Source Type: research

Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
Abstract This review article discusses the following, as yet unanswered, questions and research priorities to optimise patient management and stroke prevention in atrial fibrillation with the new direct oral anticoagulants (NOACs): 1. In patients prescribed a NOAC, can the anticoagulant effects or plasma concentrations of the NOACs be measured rapidly and reliably and, if so, can "cut-off points" between which anticoagulation is therapeutic (i.e. the "therapeutic range") be defined? 2. In patients who are taking a NOAC and bleeding (e.g. intracerebral haemorrhage), can the anticoagulant effects of the direct NOACs...
Source: Thrombosis and Haemostasis - November 28, 2013 Category: Hematology Authors: Hankey GJ Tags: Thromb Haemost Source Type: research

Optimising stroke prevention in elderly patients with atrial fibrillation.
This article is protected by copyright. All rights reserved. PMID: 27557552 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 24, 2016 Category: Hematology Authors: Lip GY Tags: J Thromb Haemost Source Type: research

Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
In conclusion, in non-valvular AF patients, cessation of OAC was independently associated with the risk of stroke, adverse cardiovascular events and mortality. Bleeding events and some variables associated with higher bleeding risk are responsible for OAC cessation. PMID: 28331926 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 23, 2017 Category: Hematology Authors: Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GY, Marín F Tags: Thromb Haemost Source Type: research

Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke
Thromb Haemost. 2023 Mar;123(3):366-376. doi: 10.1055/s-0042-1760257. Epub 2023 Mar 2.ABSTRACTINTRODUCTION: Atrial fibrillation (AF) is a common cause of stroke. Timely diagnosis of AF and treatment with oral anticoagulation (OAC) can prevent up to two-thirds of AF-related strokes. Ambulatory electrocardiographic (ECG) monitoring can identify undiagnosed AF in at-risk individuals, but the impact of population-based ECG screening on stroke is uncertain, as ongoing and published randomized controlled trials (RCTs) have generally been underpowered for stroke.METHODS AND ANALYSIS: The AF-SCREEN Collaboration, with support from...
Source: Thrombosis and Haemostasis - March 2, 2023 Category: Hematology Authors: AF SCREEN and AFFECT-EU Collaborators Source Type: research